External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Leave site
Roche and Genentech at

AACR NCI EORTC 2023

-
Coming soon
04:30 PM
Duration 3hrs Boston USA
Efficacy and safety of entrectinibâ–¼ in patients (pts) with locally advanced/metastatic NTRK or ROS1 fusion-positive (fp) solid tumors, not evaluable for the primary endpoint of STARTRK-2
Liu S, Peeters M, Ahn M-J, Lin J, Ohe Y, Yau CCT, Bordogna W, Osbourne S, Schwemmers S, Zeuner H, Goto K

Sign up or login to unlock the full suite of MEDICALLY features

Add to calendar